Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
OPCON-A is a fixed-dose ophthalmic combination of pheniramine maleate (antihistamine) and naphazoline hydrochloride (decongestant) formulated as drops for topical ocular use. It is indicated for temporary relief of ocular itching and redness associated with allergic conjunctivitis and minor eye irritation. The antihistamine blocks histamine receptors to reduce itching while the decongestant vasoconstricts blood vessels to reduce redness.
As an aging brand approaching loss of exclusivity with moderate competitive pressure, commercial teams face declining revenue and shrinking headcount; career growth limited without differentiation strategy.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on OPCON-A offers limited career growth potential given the product's LOE-approaching status and minimal linked job openings. Roles are primarily defensive, focused on protecting market share and ensuring compliance rather than driving innovation or revenue expansion.
Worked on OPCON-A at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.